Introduction

Conclusions
Heparins
• Several growth factors (VEGF, FGFs, HB-EGF, HGF, PDGF, TGF-β), adhesion proteins (P-, L-selectins) and enzymes (heparanase) that play crucial roles in cancer progression and metastasis are heparin binding proteins.
• Both unfractionated heparin and several low molecular weight heparins (LMWH) are known to inhibit experimental metastasis in animal models.
• Retrospective analyses of clinical trials in which LMWHs were used to treat hyper-coagulability in cancer patients have suggested a survival benefit for the treated groups. Many small studies evaluating the effects of UFH and LMWH in cancer patients without thrombosis have also been conducted and have generally suggested a survival benefit. However, full exploration of anti-neoplastic effects of heparin or LMWH to date has been limited due to its anti-coagulant activity.
Compounds tested
• In order to fully explore the antitumor effect of LMWH, Momenta Pharmaceuticals, Inc generated a library of HSPG-mimetics rationally engineered to exhibit reduced anti-coagulant activity while maintaining anti-tumor efficacy. M402 is the lead compound selected following invivo screening of the above series using the B16F10 model of experimental metastasis. M-ONC 202 has been designated as control compound with no detectable anti-coagulant activity and anti-tumor efficacy.
4T1 murine mammary carcinoma model
• For efficacy, survival and biodistribution studies necessitated a need for more relevant orthotopic model of tumor metastasis like the 4T1 murine mammary model which closely mimics the tumor growth and metastasis observed in Stage IV human breast cancer. Metastasis in this model is through the hematogenous route to lymph nodes, lung, liver, bone and brain and 100% animals develop and die of distal metastases if left untreated.
Heparan sulfate proteoglycans (HSPGs) play important roles in tumorigenesis by mediating tumor-stromal interactions through the presentation of growth factors, cytokines, and chemokines critical for tumor progression, survival and metastasis. M402 is a rationally engineered, non-cytotoxic HSPG mimetic, designed to disrupt tumor-host interactions. M402 binds and inhibits multiple factors including VEGF, FGF2, SDF-1α, and P-selectin. (A) Groups of female BALB/c mice (n=16) were inoculated orthotopically with 4T1 cells in the 4 th mammary fat pad on day 0. Weekly ip injection of saline or Cisplatin (1.25mg/kg), as well as saline or M402 (20mg/kg/day, delivered by sc implanted osmotic pumps) treatment was started on day 5. Primary tumors were removed on day 9 by surgery, weighed and fixed in buffered-formalin. The experiment was terminated on day 32, lung tissues were isolated and lung weight quantified (B) Blood samples were obtained by cardiac puncture. MDSCs were defined by gating on flow cytometry FSC and SSC plot which were shown to be >90% CD11b + GR-1 + . *, p<0.05; **, P<0.01 compared with saline control group. (C) Fixed primary tumors were embedded in paraffin and stained for CD31 by immunohistochemistry. Quantification of microvessel density as numbers of vessels/40x field. *, P<0.05 when compared with saline control group. 
